Cancer Screening: How Early Detection Tests Work and Who Needs Them

Finding Cancer Before It Speaks

Cancer screening is built on a single premise: find malignancies while they are small, localized, and more curable — before symptoms force a patient to a physician. The five-year survival rate for colorectal cancer detected at the localized stage is 91 percent. At the distant (metastatic) stage, it drops to 13 percent. That gap — driven in part by screening — explains why early detection has become a cornerstone of oncology.

But screening is not without complexity. A test applied to millions of healthy people will produce false positives, lead to unnecessary procedures, and occasionally detect cancers that would never have caused harm. Understanding the principles of screening — and the tradeoffs built into every recommendation — is essential for informed medical decision-making.

Principles That Make a Screening Test Valid

For a cancer screening program to benefit the population it serves, several conditions must be met:

• The cancer must have a detectable preclinical phase: There must be a window of time between when a test can detect cancer and when it would produce symptoms
• Earlier treatment must improve outcomes: Finding cancer sooner must actually lead to better survival, not just longer time living with a diagnosis (lead-time bias)
• The test must be sufficiently sensitive and specific: High sensitivity minimizes missed cancers; high specificity minimizes false positives
• The harms of screening must be outweighed by benefits: Radiation exposure, unnecessary biopsies, anxiety, and overdiagnosis must be weighed against lives saved

Types of Cancer Screening Tests

Major Screening Programs With Strong Evidence

Colorectal Cancer

Colorectal cancer is one of the most preventable common cancers because screening not only detects cancer early but also removes precancerous polyps, preventing cancer from developing. The U.S. Preventive Services Task Force (USPSTF) recommends beginning screening at age 45 for average-risk individuals. Options include:

• Colonoscopy every 10 years (gold standard; allows both diagnosis and treatment)
• Annual high-sensitivity guaiac fecal occult blood test (gFOBT) or FIT
• Stool DNA test (Cologuard) every 1 to 3 years
• CT colonography (virtual colonoscopy) every 5 years
• Flexible sigmoidoscopy every 5 years

Breast Cancer

Mammography has been shown to reduce breast cancer mortality by approximately 20 percent in randomized controlled trials. Recommendations vary by organization:

• USPSTF (2024): Biennial screening mammography beginning at age 40 (updated from age 50 in 2016)
• American Cancer Society: Annual mammography starting at age 45; option to start at 40; transition to biennial at age 55
• Women at high risk (BRCA1/2 mutations, significant family history) may benefit from annual MRI in addition to mammography, beginning earlier

Cervical Cancer

The combination of Pap smear cytology and HPV testing has transformed cervical cancer into one of the most preventable cancers. USPSTF recommendations:

• Pap smear alone every 3 years (ages 21–65)
• HPV testing alone every 5 years (ages 30–65)
• Co-testing (Pap + HPV) every 5 years (ages 30–65)

HPV vaccination with the 9-valent vaccine (Gardasil 9), recommended through age 26 and available through 45, prevents infection with the high-risk HPV types responsible for approximately 70 percent of cervical cancers.

Lung Cancer

Low-dose computed tomography (LDCT) screening for lung cancer is recommended by the USPSTF for adults aged 50 to 80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years. The National Lung Screening Trial (NLST) demonstrated a 20 percent reduction in lung cancer mortality in this high-risk population. Shared decision-making is emphasized given the high false-positive rate — approximately 95 percent of positive screens are not cancer.

Major Screening Programs — Summary of Guidelines

The Problem of Overdiagnosis

Overdiagnosis occurs when screening detects a cancer that would never have caused symptoms or death in the patient's lifetime. This is not a rare event. Estimates suggest that 20 to 50 percent of screen-detected breast cancers and up to 60 percent of thyroid cancers detected by ultrasound represent overdiagnosis. Overdiagnosed patients receive real treatment — surgery, radiation, chemotherapy — with real harms, for a cancer that posed no actual threat.

This is a key reason why not every cancer has a recommended screening program. Prostate cancer screening (PSA testing) carries a USPSTF grade C recommendation because the absolute benefit in mortality reduction is small while the harms from biopsy, treatment-related erectile dysfunction, and incontinence are substantial. Ovarian cancer has no recommended screening because available tests do not reduce mortality and lead to significant surgical harm from false positives.

Multi-Cancer Early Detection Tests

A new generation of liquid biopsy tests — analyzing cell-free DNA fragments or protein biomarkers in blood — can screen for multiple cancer types simultaneously. The Galleri test (GRAIL), available as a laboratory-developed test since 2021, screens for more than 50 cancer types using methylation patterns of cell-free DNA. Large randomized trials (including the PATHFINDER and NHS-Galleri trials) are underway to determine whether MCED tests reduce cancer mortality when used in screening populations. As of 2025, no MCED test has received FDA approval for general population screening.

This article is for informational purposes only. Consult a qualified healthcare professional before making any health decisions.